<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ%3A3SITES_Trial</id>
	<title>EBQ:3SITES Trial - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=EBQ%3A3SITES_Trial"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:3SITES_Trial&amp;action=history"/>
	<updated>2026-04-18T16:30:45Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ:3SITES_Trial&amp;diff=377277&amp;oldid=prev</id>
		<title>Rossdonaldson1: /* Major Points */</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:3SITES_Trial&amp;diff=377277&amp;oldid=prev"/>
		<updated>2025-07-30T19:50:56Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Major Points&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;es&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Revisión anterior&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revisión del 19:50 30 jul 2025&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l21&quot;&gt;Línea 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Línea 21:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Major Points==  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Major Points==  &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;{{&lt;/del&gt;CVC &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;main points}}&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Central venous catheters(CVCs) are often required to establish venous access in critically ill patients in order to administer rapid [[fluid resuscitation]], [[blood products]], and [[vasopressors]].  The sites of insertion fall into three locations: Internal jugular (IJ), subclavian, and femoral.  The major [[&lt;/ins&gt;CVC &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;catheter problems|complications]] of concern include: catheter-related bloodstream infections (CRBI), [[DVT]], and mechanical complications (e.g. pneumothorax and arterial puncture).&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;The [[EBQ:3SITES Trial|3SITES Trial]] study, a multicenter randomized trial, investigated the complications of the three anatomic sites for CVC insertion in relation to blood stream infections or DVTs. Although subclavian lines appear to have a lower infection rate, there is greater incidence of mechanical complications.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Study Design==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Study Design==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Rossdonaldson1</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=EBQ:3SITES_Trial&amp;diff=49028&amp;oldid=prev</id>
		<title>Ostermayer: Created page with &quot;{{JC info | title= Intravascular Complications of Central Venous Catheterization by Insertion Site | abbreviation=3SITES | expansion= | published=2015-09-24 | author=Parienti...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=EBQ:3SITES_Trial&amp;diff=49028&amp;oldid=prev"/>
		<updated>2015-11-28T17:36:03Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;{{JC info | title= Intravascular Complications of Central Venous Catheterization by Insertion Site | abbreviation=3SITES | expansion= | published=2015-09-24 | author=Parienti...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Página nueva&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{JC info&lt;br /&gt;
| title= Intravascular Complications of Central Venous Catheterization by Insertion Site&lt;br /&gt;
| abbreviation=3SITES&lt;br /&gt;
| expansion=&lt;br /&gt;
| published=2015-09-24&lt;br /&gt;
| author=Parienti JJ, et al&lt;br /&gt;
| journal=NEJM&lt;br /&gt;
| year=2015&lt;br /&gt;
| volume=373&lt;br /&gt;
| issue=13&lt;br /&gt;
| pages=1220-1229&lt;br /&gt;
| pmid=26398070&lt;br /&gt;
| fulltexturl=http://www.nejm.org/doi/full/10.1056/NEJMoa1500964&lt;br /&gt;
| pdfurl=http://unmhospitalist.pbworks.com/w/file/fetch/100984129/nejmoa1500964.pdf&lt;br /&gt;
| status=Complete&lt;br /&gt;
}}&lt;br /&gt;
==Clinical Question==&lt;br /&gt;
Do major complications of central venous catheters differ by site of insertion (central, subclavian and femoral)?&lt;br /&gt;
==Conclusion==&lt;br /&gt;
The subclavian site, when compared to the IJ or femoral site, is associated with fewer bloodstream infections and DVTs. The rate of mechanical complications is greatest&lt;br /&gt;
&lt;br /&gt;
==Major Points== &lt;br /&gt;
{{CVC main points}}&lt;br /&gt;
&lt;br /&gt;
==Study Design==&lt;br /&gt;
*Multicenter (10 ICUs from 4 university and 5 community hospitals in France) randomized, controlled trial&lt;br /&gt;
*N=3,471 ICU patients &lt;br /&gt;
**Subclavian (n=1,016)&lt;br /&gt;
**Jugular (n=1,284)&lt;br /&gt;
**Femoral (n=1,171)&lt;br /&gt;
*Dates: December 2011 to June 2014&lt;br /&gt;
*Analysis: Intention-to-treat&lt;br /&gt;
*Primary outcome: Major catheter-related complications (bloodstream infection or symptomatic DVT)&lt;br /&gt;
*Secondary: Major mechanical complications&lt;br /&gt;
*Median follow up: 5 days&lt;br /&gt;
==Population==&lt;br /&gt;
===Patient Demographics===&lt;br /&gt;
*Age 63, 63% male, BMI 26&lt;br /&gt;
*Illness severity: SAPS II 57.1&lt;br /&gt;
*Co-morbidities: &lt;br /&gt;
**Diabetes 20.5%&lt;br /&gt;
**Cancer 9.0%&lt;br /&gt;
**AIDS 1.4%&lt;br /&gt;
*Complicating Conditions (IJ group)&lt;br /&gt;
**Neutropenia (&amp;lt;500/mm&amp;lt;sup&amp;gt;3&amp;lt;/sup&amp;gt; 1.8%&lt;br /&gt;
**Tracheotomy 1.7%&lt;br /&gt;
**Antibiotic therapy 54.1%&lt;br /&gt;
**Anticoagulation 30.4%&lt;br /&gt;
**Parenteral nutrition 5.8%&lt;br /&gt;
&lt;br /&gt;
===Inclusion Criteria===&lt;br /&gt;
* 18 years or older&lt;br /&gt;
* Admitted to the ICU and required central venous access&lt;br /&gt;
* Had at least 2/3 acceptable insertion sites (femoral, jugular, or subclavian)&lt;br /&gt;
&lt;br /&gt;
===Exclusion Criteria===&lt;br /&gt;
* Only one access site available&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Interventions==&lt;br /&gt;
*Randomization (1:1:1) to one of the three anatomic sites(subclavian, jugular, or femoral CVC) &lt;br /&gt;
* Randomization stratified according to ICU and according to the use of antibiotics versus no therapy&lt;br /&gt;
* All ICUs used the French Haute Autorite de Sante checklist and US guidelines for preventing catheter-related infections&lt;br /&gt;
*Placement followed standard Seldinger technique with the use of anatomical landmarks or ultrasound guidance&lt;br /&gt;
*Catheter-related bloodstream infection was defined by catheter-tip colonized with the same phenotypic microorganism isolated from peripheral blood cultures&lt;br /&gt;
*Two days after CVCremoval ultrasound was used to detect asymptomatic or confirm symptomatic catheter-related DVT&lt;br /&gt;
*Sterile preparations used: &lt;br /&gt;
**Alcoholic chlorhexidine 43.1%&lt;br /&gt;
**Alcoholic povidone-iodine 43.1%&lt;br /&gt;
**Aqueous povidone-iodine 9.8%&lt;br /&gt;
*Procedural Guidance: &lt;br /&gt;
**Use of anatomical landmarks 32.7% (femoral 74%, subclavian 86%), insertion time 12.6 min, insertion failure 7.7% (subclavian 14.7%)&lt;br /&gt;
**Duration of catheterization 6.5 days&lt;br /&gt;
&lt;br /&gt;
==Outcomes==&lt;br /&gt;
===Primary Outcomes===&lt;br /&gt;
; Catheter-related bloodstream infection or symptomatic DVT:''Femoral vs subclavian:  ''25 vs. 8 (HR 3.5; 95% CI 1.5-7.8; P=0.003)&lt;br /&gt;
: ''Jugular vs subclavian:  ''23 vs. 11 (HR 2.1; 95% CI 1.0-4.3; P=0.04)&lt;br /&gt;
: ''Femoral vs jugular:  ''33 vs. 30 (HR 1.3; 95% CI 0.8-2.1; P=0.30)&lt;br /&gt;
&lt;br /&gt;
===Secondary Outcomes===&lt;br /&gt;
; Bloodstream infection:''Femoral vs subclavian:  ''11 vs. 4 (HR 3.4; 95% CI 1.5-7.8; P=0.048)&lt;br /&gt;
: ''Jugular vs subclavian:  ''13 vs. 6 (HR 2.3; 95% CI 0.8-6.2; P=0.11)&lt;br /&gt;
: ''Femoral vs jugular:  ''15 vs. 21 (HR 0.9; 95% CI 0.5-1.8; P=0.81)''  ''&lt;br /&gt;
&lt;br /&gt;
; Symptomatic DVT:''Femoral vs subclavian:  ''15 vs. 5 (HR 3.4; 95% CI 1.5-7.8; P=0.02)&lt;br /&gt;
: ''Jugular vs subclavian:  ''10 vs. 6 (HR 1.8; 95% CI 0.6-4.9; P=0.29)&lt;br /&gt;
: ''Femoral vs jugular:  ''20 vs. 9 (HR 2.4; 95% CI 1.1-5.4; P=0.04)''  '' &lt;br /&gt;
&lt;br /&gt;
==Criticisms &amp;amp; Further Discussion==&lt;br /&gt;
*This study confirms what was demonstrated in another single site study where subclavian catheters had lower infection rates.&amp;lt;ref&amp;gt;Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults 'Crit Care Med 2012'40(5):1627-34 [http://www.ncbi.nlm.nih.gov/pubmed/22511140 pubmed]&amp;lt;/ref&amp;gt;&lt;br /&gt;
*High risk patients may have been excluded from the subclavian site.&lt;br /&gt;
*Crash line complications and infections cannot be extrapolated from this data&lt;br /&gt;
*Mechanical complications were a secondary outcome and reduction in infections may not be outweighted by the risk of mechanical complications in some settings.&lt;br /&gt;
*The the study was ICU based and &amp;quot;crash lines&amp;quot; in the ER cannot be abstracted from this population.&lt;br /&gt;
*Ultrasound guidance was not randomized and use may affect results positively or negatively.&lt;br /&gt;
==External Links==&lt;br /&gt;
[http://rebelem.com/november-2015-rebelcast-all-vascular-access-episode/ RebelEM Podcast - Vascular Access]&lt;br /&gt;
==See Also==&lt;br /&gt;
*[[Central venous catheterization]]&lt;br /&gt;
==Funding==&lt;br /&gt;
*Grant from the Hospital Program for Clinical Research, French Ministry of Health&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:EBQ]]&lt;/div&gt;</summary>
		<author><name>Ostermayer</name></author>
	</entry>
</feed>